UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(d) OF THE 

SECURITIES EXCHANGE ACT OF 1934

 

 

Date of Report (Date of earliest event reported): June 5, 2014

 

 

TherapeuticsMD, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada		001-00100		87-0233535
(State or Other  Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

6800 Broken Sound Parkway NW,  Third Floor  Boca Raton, FL 33487

(Address of Principal Executive Office) (Zip Code)

Registrant's telephone number, including area code: (561) 961-1900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On June 5, 2014, TherapeuticsMD, Inc. (the "Company") held its 2014 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders of the Company considered and voted on proposals to: (1) elect nine directors, each to serve until the Company’s next annual meeting of stockholders or until their successors are elected and qualified, (2) provide a non-binding advisory vote on the compensation of the Company's named executive officers for fiscal 2013, and (3) ratify the appointment of Rosenberg Rich Baker Berman & Company, an independent registered public accounting firm, as the independent auditor of the Company for the fiscal year ending December, 31, 2014.

 

Set forth below are the final voting results for each proposal submitted to a vote of the stockholders at the Annual Meeting. For more information on the following proposals, see the Company’s 2014 Proxy Statement, as filed with the United States Securities and Exchange Commission on April 17, 2014.

 

Proposal 1: To elect nine directors, each to serve until the Company’s next annual meeting of stockholders or until their successors are elected and qualified.

 

Nominee			For				Against				Abstain				Broker Non-Votes
Tommy G. Thompson			103,364,165				0				5,010,089				0
Robert G. Finizio			108,047,164				0				327,090				0
John C.K. Milligan, IV			104,987,372				0				3,386,882				0
Brian Bernick, M.D.			104,988,172				0				3,386,082				0
Cooper C. Collins			103,653,192				0				4,721,062				0
Randall Stanicky			108,033,468				0				340,786				0
Robert V. LaPenta, Jr.			108,036,618				0				337,636				0
Jules A. Musing			108,051,177				0				323,077				0
Nicholas Segal			108,022,618				0				351,636				0

 

Proposal 2: To provide a non-binding advisory vote on the compensation of the Company’s named executive officers for fiscal 2013.

 

	For				Against				Abstain				Broker Non-Votes
	104,343,259				3,887,179				143,816				14,522,421

 

Proposal 3: To ratify the appointment of Rosenberg Rich Baker Berman & Company, an independent registered public accounting firm, as the independent auditor of the Company for the fiscal year ending December 31, 2014.

 

	For				Against				Abstain				Broker Non-Votes
	122,119,470				746,206				30,999				0

  

Each of the director nominees and proposals received the necessary votes in favor to be adopted by the Company’s stockholders at the Annual Meeting.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 11, 2014

	THERAPEUTICSMD, INC.
	By:	/s/ Daniel A. Cartwright
	Name: Title:	Daniel A. Cartwright Chief Financial Officer